Terry Guiley
Psychiatry · Potosi, MONPI 1639183320
Payments from drug & device makers
Across 307 payments — averaging $12.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corium, LLC$585
- AbbVie$516
- Avanir Pharmaceuticals, Inc.$455
- Johnson & Johnson$422
- Axsome Therapeutics, Inc.$353
- Sunovion Pharmaceuticals Inc.$345
- plus $1K from 15 others
What the payments were for
- Food & beverage$3,74799%
- Education$451%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corium, LLC | 58 | $585 |
| AbbVie(2 entities) | 53 | $516 |
| Avanir Pharmaceuticals, Inc. | 33 | $455 |
| Johnson & Johnson | 26 | $422 |
| Axsome Therapeutics, Inc. | 22 | $353 |
| Sunovion Pharmaceuticals Inc. | 45 | $345 |
| Harmony Biosciences LLC | 11 | $248 |
| Neurocrine Biosciences, Inc. | 9 | $176 |
| Otsuka America Pharmaceutical, Inc. | 8 | $131 |
| Eisai Inc. | 16 | $128 |
| Alkermes, Inc. | 5 | $102 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $100 |
| Lundbeck LLC | 4 | $59 |
| Collegium Pharmaceutical, Inc. | 3 | $44 |
| Noven Therapeutics, LLC | 2 | $27 |
| Adlon Therapeutics L.p. | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $17 |
| Vertical Pharmaceuticals, LLC | 1 | $16 |
| Grifols USA, LLC | 1 | $15 |
| Indivior Inc. | 1 | $12 |
How this compares
$3,792 in reported general payments places this provider in the 80th percentile of 680 psychiatry providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AuvelityDextromethorphan Hbr/Bupropion | 24 | $31,030 |
| Vilazodone Hcl | 13 | $1,840 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 15 | $1,498 |
| Methylphenidate Hcl | 32 | $1,321 |
| Aripiprazole | 51 | $1,284 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 25 | $1,189 |
| Duloxetine Hcl | 69 | $1,090 |
| Bupropion XlBupropion Hcl | 49 | $930 |
| Fluvoxamine Maleate | 12 | $904 |
| Methylphenidate ErMethylphenidate Hcl | 11 | $668 |
| Lamotrigine | 60 | $640 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 17 | $611 |
| Fluoxetine Hcl | 36 | $391 |
| Clonazepam | 79 | $361 |
| Quetiapine Fumarate | 24 | $333 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Axsome Therapeutics, Inc.Auvelity | $353 | $31,03024 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 680 psychiatry providers in Missouri.
Other psychiatry in Potosi
- Gregory MattingleySaint Charles$8.2M
- Junaid SyedSaint Louis$8M
- Eric CarbonellFestus$5.4M
- Ricky MofsenSaint Louis$4.9M
- Charles ConwaySaint Louis$3.8M
- Mohd MalikSaint Louis$2.8M
- Franco SicuroOlivette$2.3M
- Howard IlivickySaint Charles$2.1M
- Vadim BaramSaint Louis$1.9M
- Gary LinkerFordland$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.